drugset / Trial / NCT00322751
Concurrent Radiotherapy With Weekly Topotecan for Primary Treatment of Inoperable Localized Non-small Cell Lung Cancer
Non-randomizedSingle-groupOpen-labelTreatment
Summary
Given the activity of single-agent Topotecan in NSCLC, there is both scientific rationale and a medical interest in studying this agent in combination with radiation. In addition, Topotecan administered on a weekly basis offers advantages over the daily x 5 regimen, i.e., the convenience of administration and fewer visits to the clinic.
Timeline
- Start
- 2006-04
- Primary completion
- 2009-11
- Completion
- 2009-11
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Topotecan | Small molecule | 2 mg/m2 | — |
| Subject | Topotecan | Small molecule | 2.5 mg/m2 | — |
| Subject | Topotecan | Small molecule | 3 mg/m2 | — |
| Subject | Topotecan | Small molecule | 3.5 mg/m2 | — |
| Subject | Topotecan | Small molecule | 4 mg/m2 | — |